MedWorm: Cutaneous T cell lymphoma

Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma.

Cell Research — Tue, 16 Mar 2010 00:00:00 +0100

CONCLUSION: This work suggests that it may be possible to stratify CTCL patients into low-risk, intermediate-risk, and high-risk groups based on gene expression. Clin Cancer Res; 16(7); OF1-9. PMID: 20233883 [PubMed - as supplied by publisher] (Source: Cell Research)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

The use of synchrotron infrared microspectroscopy in the assessment of cutaneous T-cell lymphoma vs. pityriasis lichenoides chronica

Photodermatology, Photoimmunology and Photomedicine — Mon, 15 Mar 2010 00:00:00 +0100

This study was performed on 20 patients with a mean age of 50 years. They were divided into two groups: mycosis fungoides (MF) (stage IA, IB and IIA) and pityriasis lichenoides chronica (PLC). Immunophenotyping using antibodies CD3, CD4, CD8, CD20 and CD30 was performed. Synchrotron Fourier transform infrared microspectroscopy (S-FTIRM) was performed on cell nuclei to assess chemical differences between MF and PLC cases as a potential complementary screening tool. Dermal spectra of both MF and PLC were compared using principal components analysis (PCA) of the S-FTIRM data. All PLC spectra was clustered together. However, the MF spectra formed two clusters, one that grouped with the PLC and the other grouped separately. Moreover, protein and nucleic acids showed highly significant differenc...

Bcl-2 expression in mycosis fungoides before and after PUVA therapy

Photodermatology, Photoimmunology and Photomedicine — Mon, 15 Mar 2010 00:00:00 +0100

In conclusion, a lack of decline in the bcl-2 level and the absence of clinical or histopathological correlation with the bcl-2 level before and after PUVA therapy in MF patients suggest that PUVA-induced apoptosis in MF cases may occur through pathways other than bcl-2 inhibition. (Source: Photodermatology, Photoimmunology and Photomedicine)

Denileukin diftitox improved overall response rate in cutaneous T-cell lymphoma

HemOncToday.com — Fri, 12 Mar 2010 10:11:00 +0100

(Source: HemOncToday.com)

Phase III trial of denileukin diftitox for patients with cutaneous T-cell lymphoma shows benefit

NeLM - News — Wed, 10 Mar 2010 00:00:00 +0100

Source: JCO Area: News According to research published early online in the Journal of Clinical Oncology, denileukin diftitox (DD) produces a statistically significant and durable effect on overall response rate (ORR) and progression-free survival (PFS) in patients with early- and late-stage cutaneous T-cell lymphoma (CTCL). Researchers evaluated the efficacy and safety of two doses of DD, a recombinant fusion protein targeting IL-2 receptor-expressing malignant T lymphocytes, in patients with biopsy-confirmed stage IA to III, CD25 assay-positive CTCL, including the mycosis fungoides and Sézary syndrome forms of the disease, who had received up to three prior therapies. The primary end point was ORR. Patients were randomised to receive DD 9 mcg/kg/day (n = 45), DD 18...

Synthesis of N-Hydroxycinnamides Capped with a Naturally Occurring Moiety as Inhibitors of Histone Deacetylase.

ChemMedChem — Fri, 05 Mar 2010 00:00:00 +0100

In this study we investigated the effectiveness of osthole, a hydrophobic Chinese herbal compound, as the surface recognition cap in hydroxamate-based compounds as inhibitors of HDAC. Nine novel osthole-based N-hydroxycinnamides were synthesized and screened for enzyme inhibition activity. Compounds 9 d, 9 e, 9 g exhibited inhibitory activities (IC(50)=24.5, 20.0, 19.6 nM) against nuclear HDACs in HeLa cells comparable to that of suberoylanilide hydroxamic acid (SAHA; IC(50)=24.5 nM), a potent inhibitor clinically used for the treatment of cutaneous T-cell lymphoma (CTCL). While compounds 9 d and 9 e showed SAHA-like activity towards HDAC1 and HDAC6, compound 9 g was more selective for HDAC1. Compound 9 d exhibited the best cellular effect, which was comparable to that of SAHA, of enhancin...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.

Cellular and Molecular Biology Letters — Fri, 05 Mar 2010 00:00:00 +0100

In this study, we investigated the specific role of STAT3, a major component of the STAT family, in growth and survival of human CTCL cell line Hut78. Western immunoblot analysis showed elevated expression of STAT3 and phospho-STAT3(Y705) in human CTCL cells as compared to freshly isolated peripheral blood lymphocytes (PBLs). Specific knockdown of STAT3 expression in Hut78 cells by RNA interference induced morphological and biochemical changes indicating apoptotic cell death. Moreover, STAT3 inhibition downregulated the expression of Bcl2 family of anti-apoptotic gene Bcl-xL. These observations suggest that STAT3 is required for the survival of CTCL cells and strongly indicate that targeting STAT3 using siRNA techniques may serve a novel therapeutic strategy for the treatment of CTCL. ...

Primary Cutaneous CD30+ Lymphoproliferative Disorders.

Actas Dermo-Sifiliograficas — Mon, 01 Mar 2010 00:00:00 +0100

Authors: Calzado-Villarreal L, Polo-Rodríguez I, Ortiz-Romero PL CD30+ lymphoproliferative disorders are the most common group of cutaneous T-cell lymphomas after mycosis fungoides and its subtypes. This group includes lymphomatoid papulosis and CD30+ anaplastic large-cell lymphoma; these 2 entities are the extremes of a spectrum with numerous intermediate varieties in which it is not possible to establish a clear diagnosis based on clinical and histopathologic criteria. CD30+ lymphoproliferative disorders must be differentiated from other lymphoproliferative diseases with CD30+ cells in the tumor infiltrates, such as mycosis fungoides or Hodgkin disease, and also from other inflammatory conditions or nonhematological neoplasms that can include this cell type, such as pityriasis l...

Role of Synchrotron infra red microspectroscopy in studying epidermotropism of cutaneous T-cell lymphoma

Journal of the European Academy of Dermatology and Venereology — Thu, 25 Feb 2010 00:00:00 +0100

Conclusions The biochemical analysis of protein, RNA and DNA with Synchrotron IR microspectroscopy is a promising tool for studying epidermotropism in cutaneous T-cell lymphoma. (Source: Journal of the European Academy of Dermatology and Venereology)

Methotrexate: Mycosis fungoides in an elderly patient?: case report

Reactions — Mon, 22 Feb 2010 14:16:47 +0100

(Source: Reactions)

Development of a Prominent Granulomatous Eruption after Interferon-gamma Therapy in a Patient with Mycosis Fungoides.

Acta Derm Venereol A... — Sun, 21 Feb 2010 21:20:56 +0100

Authors: Haruyama S, Sugita K, Kawakami C, Nakamura M, Tokura Y PMID: 20169308 [PubMed - in process] (Source: Acta Derm Venereol A...)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

Drugs — Sat, 20 Feb 2010 14:12:41 +0100

(Source: Drugs)

Phototherapy may induce IGH-like lesions

MedWire News - Dermatology — Fri, 19 Feb 2010 00:00:00 +0100

Phototherapy treatment for mycosis fungoides may induce skin eruptions similar to those seen with idiopathic guttate hypomelanosis, show study results. (Source: MedWire News - Dermatology)

Combination therapy with extracorporeal photopheresis, interferon-α, PUVA and topical corticosteroids in the management of Sézary syndrome

JDDG — Thu, 18 Feb 2010 00:00:00 +0100

Conclusions: The investigated combination therapy was effective and well-tolerated in a subgroup of SS patients but needs to be evaluated in a larger patient population. (Source: JDDG)

Idiopathic guttate hypomelanosis-like lesions in patients with mycosis fungoides: a new adverse effect of phototherapy

Journal of the European Academy of Dermatology and Venereology — Wed, 17 Feb 2010 00:00:00 +0100

Conclusions Phototherapy may induce an eruption bearing similar clinical and histopathological features to IGH. The eruption is rare, appears to emerge only after prolonged therapy and seems to be reversible upon discontinuation of phototherapy. IGH-like eruption should be added to the list of side-effects of phototherapy. (Source: Journal of the European Academy of Dermatology and Venereology)

Epidermotropic Merkel cell carcinoma: A case series with histopathologic examination

Journal of the American Academy of Dermatology — Tue, 16 Feb 2010 14:09:30 +0100

Conclusion: The data presented reinforce the differential diagnosis of tumors with an epidermotropic growth pattern and the importance of immunohistochemical staining in the histologic workup of such tumors: squamous cell carcinoma in situ, melanoma, mycosis fungoides, eccrine porocarcinoma, sebaceous carcinoma of the eyelid, mammary and extramammary Paget disease, MCC, and epidermotropic metastases. It is notable that 3 of 6 identified tumors were located on the eyelid; further study of epidermotropic MCC may shed more light on this finding, either as an unusual coincidence or a finding with unexplained significance. (Source: Journal of the American Academy of Dermatology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

A mouse model for the Sezary syndrome

Journal of Experimental and Clinical Cancer Research — Thu, 11 Feb 2010 00:00:00 +0100

Conclusion: Although the mouse model does not exactly match the human disease, it will be suited for tests of new substances for the treatment of the Sezary syndrome. The formation of an isolated tumor on the skin has the advantage that the effect of a potential drug can be directly monitored without the use of invasive methods. (Source: Journal of Experimental and Clinical Cancer Research)

HDAC Inhibitors: Much to Learn About Effective Therapy

Cancer Network — Wed, 10 Feb 2010 13:30:01 +0100

Shabason and colleagues’ review of the development of histone deacetylase (HDAC) inhibitors as treatment for cancers is timely, with an emphasis on therapeutic strategies combining HDAC inhibitors and radiation therapy. As the authors indicate, vorinostat (Zolinza)—originally known as suberoylanilide hydroxamic acid, or SAHA—was the first of the HDAC inhibitors approved by the US Food and Drug Administration (FDA) for clinical use in the treatment of cutaneous T-cell lymphoma (CTCL).[1] In November 2009, a second HDAC inhibitor—romidepsin (Istodax)—received FDA approval for the treatment of CTCL. Currently there is a great deal of competition in the HDAC inhibitor field, as several new and, hopefully, more effective compounds are being developed and entering clinical trials.[2] (...

HDAC Inhibitors in Cancer Care

Cancer Network — Tue, 09 Feb 2010 12:00:00 +0100

The epigenetic control of gene expression has been shown to play an important role in cancer initiation, progression, and resistance. Thus, agents that modify the epigenetic environment of tumors will likely be an important addition to the anticancer arsenal. Specifically, there is much interest in modulating histone acetylation using a new class of drugs, histone deacetylase (HDAC) inhibitors. Preclinical data have demonstrated the efficacy of various HDAC inhibitors as anticancer agents, with the greatest effects shown when HDAC inhibitors are used in combination with other therapies. As a result of encouraging preclinical data, numerous HDAC inhibitors are being investigated in clinical trials either as monotherapies or in conjunction with other treatments such as chemotherapy, biologic...

Primary cutaneous lymphoma: An overview based on the WHO–EORTC classification

Diagnostic Histopathology — Mon, 08 Feb 2010 00:00:00 +0100

Abstract: Primary cutaneous lymphomas, defined by their presentation in the skin in the absence of extracutaneous disease at diagnosis, are a heterogenous group of T- and B-cell neoplasms. The commonest, mycosis fungoides, has no nodal counterpart but others show morphological, immunophenotypic and genotypic similarities to primary extracutaneous lymphomas and yet display very different clinical behaviour. This review discusses the salient features of the major entities in the context of the recent World Health Organization/European Organization for the Research and Treatment of Cancer (WHO/EORTC) classification of primary cutaneous lymphoma. In particular, it emphasizes the importance of close clinicopathological correlation and detailed immunophenotyping in their diagnosis. (Source: Diag...

Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases.

Veterinary Dermatology — Fri, 05 Feb 2010 00:00:00 +0100

Authors: Fontaine J, Heimann M, Day MJ This retrospective study reviewed the clinical, histological and immunohistochemical features of 30 European cases of canine cutaneous epitheliotropic T-cell lymphoma (CETL). The clinical presentation was highly variable and was not associated with the disease subtype. Diffuse erythema (86.6%) with scaling (60%) and focal hypopigmentation (50%) were the most common lesions. The skin was uniformly involved but muco-cutaneous junctions or mucosae were affected in 50% of cases. The median age at diagnosis was 10 years (SD 2.79, range 4-15) and the median time between onset and final diagnosis was 5 months (SD 3.79, range 0-12). Five cases occurred in Bichon Frises. There was no evidence of a previous history of chronic dermatitis in any cases. Histol...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Journal of Hematology and Oncology — Thu, 04 Feb 2010 00:00:00 +0100

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs. One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combi...

'Epidermotropism' vs. 'exocytosis' of lymphocytes 101: definition of terms

Journal of Cutaneous Pathology — Thu, 04 Feb 2010 00:00:00 +0100

In this study, definitions of both terms were requested from 34 experts. In definitions provided by 19 responders, 'epidermotropism' correlated with MF/CTCL, and 'exocytosis' correlated with benign conditions. Use of these terms often reflected the observer's interpretation, as they were not always used in purely descriptive fashion. Fung MA. 'Epidermotropism' vs. 'exocytosis' of lymphocytes 101: definition of terms. (Source: Journal of Cutaneous Pathology)

Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification

Journal of Cutaneous Pathology — Thu, 04 Feb 2010 00:00:00 +0100

Conclusions: Most non-MF PCTCL can be classified according to the WHO-EORTC classification. The relative frequencies are similar to European experience. Non-MF PCTCL is a heterogeneous group with a favorable outcome compared to SC-TCL, especially PC-ALCL and CTLCD4. Separation of non-MF PCTCL into indolent and aggressive groups appears clinically significant and may provide direction for therapeutic decisions. Weaver J, Mahindra AK, Pohlman B, Jin T, His ED. Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification. (Source: Journal of Cutaneous Pathology)

Vorinostat interferes with the signaling transduction pathway of T cell receptor and synergizes with PI3K inhibitors in cutaneous T-cell lymphoma.

Haematologica — Thu, 04 Feb 2010 00:00:00 +0100

Conclusions These results demonstrate the potential targets of SAHA, underlining the importance of TCR signaling inhibition following vorinostat treatment. Additionaly, we show that combination therapies involving HDACi and inhibitors of PI3K can be potentially efficacious for the treatment of CTCL. PMID: 20133897 [PubMed - as supplied by publisher] (Source: Haematologica)

Deal watch: Celgene acquires Gloucester Pharmaceuticals, gaining approved HDAC inhibitor

Nature Reviews Drug Discovery — Mon, 01 Feb 2010 14:19:42 +0100

Deal watch: Celgene acquires Gloucester Pharmaceuticals, gaining approved HDAC inhibitor Nature Reviews Drug Discovery 9, 94 (2010). doi:10.1038/nrd3112 Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL) (Source: Nature Reviews Drug Discovery)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Leukaemic Cutaneous T-cell Lymphoma-Manifesting Papuloerythroderma with CD3- CD4+ Phenotype.

Acta Derm Venereol A... — Sat, 30 Jan 2010 10:22:03 +0100

We describe here an indolent leukaemic patient with cutaneous T-cell lymphoma, who initially had a nodulo-tumourous eruption with a crop of solid papules, but finally presented with papuloerythroderma. Histologically, the skin lesions showed non-epidermotropic dermal infiltration of atypical lymphocytes with lymphoid follicles and a granulomatous change. The circulating malignant CD4+CCR4+ T cells lacked the expression of T-cell receptor and did not respond to concanavalin A. The unresponsiveness of T cells to the T-cell mitogen may be associated with the non-epidermotropic behaviour of the tumour cells and the initially non-erythrodermic eruption. PMID: 20107729 [PubMed - in process] (Source: Acta Derm Venereol A...)

Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat.

Acta Derm Venereol A... — Sat, 30 Jan 2010 10:22:03 +0100

We present here management strategies for cutaneous lymphoma-associated pruritus. PMID: 20107719 [PubMed - in process] (Source: Acta Derm Venereol A...)

CDKN2A–CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma

Modern Pathology AOP — Fri, 29 Jan 2010 00:00:00 +0100

CDKN2A–CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma Modern Pathology advance online publication, January 29, 2010. doi:10.1038/modpathol.2009.196 Authors: Elodie Laharanne, Edith Chevret, Yamina Idrissi, Catherine Gentil, Michel Longy, Jackie Ferrer, Pierre Dubus, Thomas Jouary, Béatrice Vergier, Marie Beylot-Barry & Jean-Philippe Merlio (Source: Modern Pathology AOP)

Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma

Archives of Dermatological Research — Thu, 28 Jan 2010 17:59:53 +0100

In this study, we analyzed the complexity of the peripheral blood T cell repertoire with a sensitive b-variable (BV) complementarity-determining region 3 (CDR3) spectratyping analysis and flow cytometry in three-stage IV CTCL/Sezary syndrome patients who achieved complete clinical remission after therapy. The T cell repertoire of peripheral blood T cells before treatment was profoundly abnormal across multiple BV subfamilies. Following treatment, CDR3 spectratype patterns showed dramatic restoration of normal diversity and complexity. However, absolute CD4 counts across multiple BV families remained low for many months, even after identifiable circulating malignant T cell populations were eliminated. These data suggest that the diversity of the T cell repertoire can be recovered afte...

Pleural Mesothelioma Phase III Clinical Trial Will Continue

Asbestos and Mesothelioma News — Wed, 27 Jan 2010 15:33:27 +0100

An independent Data Safety and Monitoring Board has recently recommended the continuation of Merck’s VANTAGE 14, a phase III clinical trial studying the experimental use of vorinostat in patients with advanced malignant pleural mesothelioma. According to their Web site, Merck & Co. Inc. is the second-largest pharmaceutical company in the world. Their researchers have helped find new ways to treat and prevent illness while maintaining a strong dedication to developing animal care products. The clinical trial is specifically studying patients who have already received treatment involving the chemotherapy drug pemetrexed (also known as the brand name Alimta). Vorinostat (marketed as ZOLINZA) is an oral histone deacetylase inhibitor made by Merck that is currently being used for trea...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Tumor Necrosis Factor (TNF) and Lymphotoxin-{alpha} (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium

American Journal of Epidemiology — Wed, 20 Jan 2010 04:44:36 +0100

In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF –308G>A (rs1800629), lymphotoxin- (LTA) 252A>G (rs909253), IL10 –3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-sided tests. Consistent with previous findings, odds ratios were increased for "new" ...

Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases

Journal of the American Academy of Dermatology — Mon, 18 Jan 2010 00:00:00 +0100

Conclusions: Folliculotropic MF is a rare but well-defined clinicopathological variant of MF. Although refractory to standard therapies used in classic MF, most of our patients showed only slow disease progression. (Source: Journal of the American Academy of Dermatology)

BioCryst's CTCL Pivotal Study Achieves Enrollment Target

Health News from Medical News Today — Sat, 16 Jan 2010 09:00:00 +0100

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it has achieved its protocol specified objective of enrolling 100 late-stage patients (Stage IIB to IVA) in its pivotal study for forodesine in the treatment of cutaneous T-cell lymphoma (CTCL). Top-line data is expected in the second half of 2010. Additionally, BioCryst's exploratory Phase 2 study for forodesine in subjects with chronic lymphocytic leukemia (CLL) is continuing to progress and has enrolled over half of its targeted number of patients... (Source: Health News from Medical News Today)

BioCryst's CTCL Pivotal Study Achieves Enrollment Target

Lymphoma / Leukemia News From Medical News Today — Sat, 16 Jan 2010 09:00:00 +0100

The role of immunohistochemical analysis in the diagnosis of parapsoriasis.

Acta Histochemica — Sat, 16 Jan 2010 00:00:00 +0100

Authors: Bordignon M, Belloni-Fortina A, Pigozzi B, Saponeri A, Alaibac M Parapsoriasis is a chronic dermatosis whose biological distinction from early mycosis fungoides, the most frequent form of cutaneous T-cell lymphoma, is still not clearly defined. Two types of parapsoriasis have been delineated: large-plaque parapsoriasis and small-plaque parapsoriasis. The lack of clinical and histological features, which may allow distinguishing parapsoriasis from early mycosis fungoides has prompted several investigations to assess the role of immunohistochemistry in establishing a conclusive diagnosis of these conditions. However, the additional data obtained by immunohistochemical analysis concerning the CD4/CD8 ratio, the aberrant expression of T-cell antigens and the expression of prolifer...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Localized lymphomatoid papulosis

Journal of the American Academy of Dermatology — Fri, 15 Jan 2010 14:02:07 +0100

We report a case of LyP with an unusual localized presentation. (Source: Journal of the American Academy of Dermatology)

Celgene Completes Acquisition of Gloucester Pharmaceuticals

HSMN NewsFeed — Fri, 15 Jan 2010 14:00:35 +0100

Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX® (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First H... Biopharmaceuticals, Mergers & AcquisitionsCelgene, Gloucester Pharmaceuticals (Source: HSMN NewsFeed)

Celgene Completes Acquisition of Gloucester Pharmaceuticals

Drugs.com - Pharma News — Fri, 15 Jan 2010 13:10:15 +0100

Primary cutaneous CD30+ large-cell lymphoma presenting as a scrotal plaque.

Dermatol Online J — Thu, 31 Dec 2009 16:04:02 +0100

We report a patient with a one-year history of an enlarging scrotal plaque. Skin biopsy stained positive for CD30, and after thorough systemic evaluation, a diagnosis of primary cutaneous CD30+ LCL was made. Most commonly CD30+ LCL presents on the extremities and trunk. We present the first case to our knowledge of a patient initially presenting with a solitary scrotal nodule. When primary cutaneous CD30+ LCL is suspected, it is important to conduct a thorough systemic evaluation for systemic LCL and immunohistological studies for CD30- types. Ruling these conditions out will prevent unnecessarily aggressive treatment for primary cutaneous CD30+ LCL, an indolent disease with a favorable prognosis. PMID: 20040259 [PubMed - in process] (Source: Dermatol Online J)

[Extracorporeal photochemotherapy.]

Transfusion Clinique et Biologique — Mon, 28 Dec 2009 00:00:00 +0100

Authors: Viguier M, Pouthier F, Tiberghien P, Aubin F Photopheresis or extracorporeal photochemotherapy (ECP) is a cellular therapy which combines a leukapheresis followed by ex vivo treatment using psoralen and ultraviolet A irradiation before reinfusion into the patient. Its mechanisms of action remain unclear and selective photodestruction of leukocytes cannot explain the long-lasting immunomodulatory effects. Recent studies demonstrated that ECP down regulates the immune response and induces tolerance through the maturation of dendritic cells and the production of regulatory T cells. Based on these effects, ECP is mainly used for treatment of Sezary syndrome, graft-versus-host disease, organ graft rejection and autoimmune diseases. However, it is still not clear how ECP both activa...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome

Journal of Dermatological Science — Thu, 24 Dec 2009 14:00:24 +0100

Conclusion: Patient age and stage are the most important clinical prognostic factors in Japanese patients with MF and SS. The revised staging system is useful for predicting survival of the patients, but at least a subpopulation of stage IIIA patients may have a favorable prognosis. (Source: Journal of Dermatological Science)

Applicability and Prognostic Value of the New TNM Classification System in 135 Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma [Study]

Archives of Dermatology — Mon, 21 Dec 2009 20:52:29 +0100

Conclusions The new TNM system can be applied well to patients with C-ALCL and may provide prognostic information, in particular when combined with site of presentation. Patients with T2 or T3 disease with skin lesions on the leg may have reduced survival and require close surveillance during follow-up. (Source: Archives of Dermatology)

Allos Therapeutics' FOLOTYN™ Shows Activity In A Dose Finding Phase 1 Study Of Relapsed Or Refractory Cutaneous T-Cell Lymphoma

Health News from Medical News Today — Thu, 10 Dec 2009 12:00:00 +0100

Allos Therapeutics, Inc. (NASDAQ: ALTH) announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). These data were showcased during an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA. Data were presented on 31 patients with relapsed or refractory CTCL who received a median of 4 prior systemic therapies... (Source: Health News from Medical News Today)

Allos Therapeutics' FOLOTYN™ Shows Activity In A Dose Finding Phase 1 Study Of Relapsed Or Refractory Cutaneous T-Cell Lymphoma

Cancer / Oncology News From Medical News Today — Thu, 10 Dec 2009 12:00:00 +0100

Allos Therapeutics, Inc. (NASDAQ: ALTH) announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). These data were showcased during an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA... (Source: Cancer / Oncology News From Medical News Today)

Allos Therapeutics' FOLOTYN™ Shows Activity In A Dose Finding Phase 1 Study Of Relapsed Or Refractory Cutaneous T-Cell Lymphoma

Lymphoma / Leukemia News From Medical News Today — Thu, 10 Dec 2009 12:00:00 +0100

Allos Therapeutics, Inc. (NASDAQ: ALTH) announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). These data were showcased during an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA... (Source: Lymphoma / Leukemia News From Medical News Today)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma

Drugs.com - Clinical Trials — Tue, 08 Dec 2009 20:28:38 +0100

-- Named One of the “Best of ASH” Presentations at the ASH Annual Meeting-- NEW ORLEANS & WESTMINSTER, Colo.--(BUSINESS WIRE)--Dec 8, 2009 - Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced updated data from its ongoing... (Source: Drugs.com - Clinical Trials)

Cutaneous T-cell lymphoma occurring with a melanocytic proliferation, masquerading as a nonhealing ulcer with reactive changes

Journal of Cutaneous Pathology — Tue, 08 Dec 2009 00:00:00 +0100

(Source: Journal of Cutaneous Pathology)

Gloucester Pharmaceuticals Presents ISTODAX Data Demonstrating Clinical Benefit in Patients with CTCL Including Blood Involvement at ASH Annual Meeting

Drugs.com - Clinical Trials — Mon, 07 Dec 2009 19:20:04 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 6, 2009 - Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester's registration study in cutaneous... (Source: Drugs.com - Clinical Trials)

Celgene to Acquire Gloucester Pharmaceuticals

HSMN NewsFeed — Mon, 07 Dec 2009 14:57:06 +0100

Commercial Launch of Novel HDAC Inhibitor, ISTODAX(R) (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted for Early 2010 ISTODAX Registration Special Protocol Assessment (SPA) Trial for Peripheral T-Cell Lymphoma (PTCL) - Accrua... Biopharmaceuticals, Oncology, Mergers & AcquisitionsCelgene, Gloucester Pharmaceuticals, ISTODAX, romidepsin, lymphoma (Source: HSMN NewsFeed)

Spectrum of CD30+ Lymphoid Proliferations in the Eyelid: Lymphomatoid Papulosis, Cutaneous Anaplastic Large Cell Lymphoma, and Anaplastic Large Cell Lymphoma

Ophthalmology — Mon, 07 Dec 2009 00:00:00 +0100

Conclusions: The CD30+ lymphoid proliferations represent a spectrum of conditions ranging from indolent LyP, to moderately aggressive cALCL, to highly aggressive ALCL. Interpretation of the pathologic findings in CD30+ lymphoid proliferations is based in part on clinical findings.Financial Disclosure(s): The authors have no proprietary or commercial interest in any material discussed in this article. (Source: Ophthalmology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Localized cutaneous T cell lymphoma presenting as disfiguring facial lesions.

Dermatol Online J — Thu, 03 Dec 2009 20:46:04 +0100

We report a case of a 27-year-old male patient with localized cutaneous T cell lymphoma presenting as disfiguring lesions on the face. PMID: 19951650 [PubMed - in process] (Source: Dermatol Online J)

News in brief

Nature Reviews Drug Discovery — Tue, 01 Dec 2009 14:37:08 +0100

Nature Reviews Drug Discovery 8, 921 (2009). doi:10.1038/nrd3071 Trio of recent anticancer drug approvalsThe FDA has approved pazopanib (Votrient; GlaxoSmithKline) for renal cell carcinoma (RCC), ofatumumab (Arzerra; Genmab/GlaxoSmithKline) for chronic lymphocytic leukaemia (CLL) and romidepsin (Istodax; Gloucester Pharmaceuticals) for cutaneous T cell lymphoma (CTCL).The lowdown: Pazopanib, a small molecule that (Source: Nature Reviews Drug Discovery)

T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression

British Journal of Dermatology — Tue, 01 Dec 2009 00:00:00 +0100

(Source: British Journal of Dermatology)

Granulomatous slack skin: assessment of disease progression and treatment response using positron emission tomography/computed tomography.

Clinical Lymphoma and Myeloma — Tue, 01 Dec 2009 00:00:00 +0100

Authors: Sheng Y, Chen L, Huang Z, Mu Z, Kong J, Luo Y, Yang Q Granulomatous slack skin (GSS) is an extremely rare subtype of cutaneous T-cell lymphoma. A 14-year-old boy had suffered from progressive infiltrative erythema and plaques that gradually evolved into lax masses and pendulous skin on his axilla, anterior wall of the abdomen, bilateral inguinal region, and thighs. Histopathologic examination of the skin lesion and inguinal lymph node demonstrated granulomatous infiltration with multinucleated giant cells. Positron emission tomography (PET)/computed tomography (CT) scan was performed after acute exacerbation and exhibited slightly high fluorodeoxyglucose (FDG) distribution of skin lesions, without any evidence of abnormality in the metabolism of FDG in lymph nodes or other ext...

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

Clinical Lymphoma and Myeloma — Tue, 01 Dec 2009 00:00:00 +0100

Conclusion: This post hoc subset analysis provides evidence for the long-term safety and clinical benefit of vorinostat in heavily pretreated patients with CTCL, regardless of previous treatment failures. PMID: 19951879 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

We should have a dream: unlocking the workings of the genome in cutaneous T-cell lymphomas.

Clinical Lymphoma and Myeloma — Tue, 01 Dec 2009 00:00:00 +0100

Authors: Porcu P, Wong HK PMID: 19951878 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)

Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.

Oncology (Williston Park, N.Y.) — Mon, 30 Nov 2009 00:00:00 +0100

Authors: Kadin ME Primary cutaneous CD30+ T-cell lymphoproliferative disorders (PCLPDs) are the second most common type of cutaneous T-cell lymphoma. These disorders comprise a spectrum of clinically benign lymphomatoidpapulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (ALCL). The peak incidence of LyP is in the 5th decade of life, and the incidence of primary cutaneous ALCL peaks in the 6th decade, but children are also affected. Both LyP and primary cutaneous ALCL have an excellent prognosis. However, LyP is associated with development of malignant lymphoma (mycosis fungoides, Hodgkin lymphoma, or ALCL) in 20% of cases, and also with an increased risk of non-lymphoid cancers. The diagnosis of LyP is difficult and often delayed. Primary cutaneous ALCL must be disting...

Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma

Journal of the American Academy of Dermatology — Mon, 30 Nov 2009 00:00:00 +0100

We present two cases of the clinically aggressive subtype of primary cutaneous epidermotropic CD8+ cutaneous T-cell lymphoma and review the current literature, clinical behavior, and recommendations for treatment distinct from that of more common CD4+ variants of cutaneous T-cell lymphoma. (Source: Journal of the American Academy of Dermatology)

Adult T-cell leukemia–lymphoma associated with follicular mucinosis

The Journal of Dermatology — Thu, 26 Nov 2009 00:00:00 +0100

We report a 49-year-old male patient who had pruritic follicular papules and erythemas clinically, and follicular and perifollicular infiltrates and follicular mucin deposition histopathologically. The patient showed 11% of flower-shaped atypical lymphocytes in blood examination and positive human T-cell leukemia virus type 1 antibody in serology, consistent with the chronic type of ATLL. This case seems to be a very rare association of follicular mucinosis and chronic ATLL, suggesting that malignant T cells may have a feature of folliculotropism as well as epidermotropism. (Source: The Journal of Dermatology)

Gloucester Pharmaceuticals to Present Positive Results from Multiple Studies of ISTODAX at the ASH Annual Meeting

Drugs.com - Clinical Trials — Wed, 25 Nov 2009 20:22:44 +0100

--Poster presentations on studies in cutaneous T-cell, peripheral T-cell and B-cell lymphoma-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 24, 2009 - Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical... (Source: Drugs.com - Clinical Trials)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options

National Comprehensive Cancer Network — Wed, 25 Nov 2009 00:00:00 +0100

Following the FDA approvals of two new therapies for Non-Hodgkin’s Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra™, GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). November 23, 2009 FORT WASHINGTON, PA — Two recent FDA approvals have pro... (Source: National Comprehensive Cancer Network)

Immunomodulatory therapy of cutaneous T-cell lymphoma: A multimodality approach in advanced disease

Journal of the American Academy of Dermatology — Thu, 19 Nov 2009 14:05:32 +0100

Dialogues in Dermatology, a monthly audio program from the American Academy of Dermatology, contains discussions between dermatologists on timely topics. Commentaries from Dialogues Editor-in-Chief Jacqueline M. Junkins-Hopkins, MD, are provided after each discussion as a topic summary and are provided here as a special service to readers of the Journal of the American Academy of Dermatology. (Source: Journal of the American Academy of Dermatology)

Correction

Journal of the American Academy of Dermatology — Thu, 19 Nov 2009 14:05:32 +0100

Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001-17. On page 1002 of the article above, the following statement was incorrect: Patients with mild psoriasis have a relative risk of 1.42 and 3.18 of developing Hodgkin's lymphoma and CTCL, respectively. Patients with severe psoriasis have a relative risk of 4.10 and 10.75 of developing Hodgkin's lymphoma and CTCL, respectively. (Source: Journal of the American Academy of Dermatology)

Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides

Journal of the European Academy of Dermatology and Venereology — Thu, 19 Nov 2009 00:00:00 +0100

Conclusions Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF. (Source: Journal of the European Academy of Dermatology and Venereology)

Folliculotropic mycosis fungoides with eosinophilia and CD30+ large-cell transformation: a case with a fatal outcome presenting with multifocal lesions and leonine facies

Clinical And Experimental Dermatology — Thu, 19 Nov 2009 00:00:00 +0100

We report a case of folliculotropic mycosis fungoides (FMF) presenting with multiple ulcerative nodular lesions and persistent eosinophilia. Severe facial lesions resulted in a leonine appearance. On histopathological examination, nodular infiltration of large CD30+ large cells was seen. When the previous biopsy specimens were reviewed, marked folliculotropism with atypical lymphocytes was identified in previous specimens 20 years before the blastic transformation. CC chemokine receptor 3 was expressed in tumour cells, whereas CXC chemokine receptor 3 was negative. Expression of interleukin (IL)-5 was detected in a few mononuclear lymphoid cells. This case demonstrates that T helper (Th)2-polarized tumour cells may produce Th2 cytokines including IL-5, which suggests that cytokines and che...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease

Transfusion and Apheresis Science — Wed, 18 Nov 2009 14:25:08 +0100

Abstract: Acute and chronic graft versus host disease are frequent and potentially severe complications of allogeneic hematopoietic stem cell transplantation and are among the leading causes of non-relapse transplant-related mortality. For patients with steroid refractory disease, prognosis is particularly poor and although a variety of treatment options are available, responses are commonly transient and the side effects often intolerable. Since it was first introduced for the treatment of cutaneous T-cell lymphoma, extracorporeal photo-apheresis has been utilized as an immunomodulatory therapy for certain autoimmune diseases and solid organ transplant rejection. Recently, extracorporeal photo-apheresis has become a promising alternative for patients with graft versus host disease with di...

Contribution of Dermatologic Surgery in War

Dermatologic Surgery — Fri, 13 Nov 2009 00:00:00 +0100

This report outlines the important contribution of dermatologic surgery in the combat environment. The authors have indicated no significant interest with commercial supporters. (Source: Dermatologic Surgery)

FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma

Health News from Medical News Today — Thu, 12 Nov 2009 19:00:00 +0100

The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin) is injectable and is marketed by Gloucester Pharmaceuticals Inc of Cambridge, Massachusetts. Every year, about 1,500 Americans are newly diagnosed with CTCL, a type of non-Hodgkin's lymphoma. (Source: Health News from Medical News Today)

FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma

Cancer / Oncology News From Medical News Today — Thu, 12 Nov 2009 19:00:00 +0100

How I treat mycosis fungoides and Sezary syndrome

Blood — Thu, 12 Nov 2009 17:38:04 +0100

The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a "stage-based" approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy. Systemic approaches are used for recalcitrant early-stage disease, advanced-stage disease (IIB-IV), and transformed disease and include retinoids, such as bexarotene, inte...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations

British Journal of Haematology — Thu, 12 Nov 2009 00:00:00 +0100

In conclusion, gene expression profiling is beginning to change the pathological classification, the prognosis profiles and the therapeutic approach in T-cell lymphomas. (Source: British Journal of Haematology)

Immunoelectron microscopy in mycosis fungoides and benign dermatoses. Expression of CD3, CD4 and CD7 receptors.

Neoplasma — Wed, 11 Nov 2009 11:46:23 +0100

Authors: Grzanka AA, Placek W, Grzanka A, Sokolowska-Wojdylo M, Zuryn A Mycosis fungoides is an epidermotropic cutaneous T-cell lymphoma (CTCL).Specimens for presented study were taken from sixteen patients with MF confirmed by immunohistochemical methods and PCR and from nine patients with benign dermatoses. To demonstrate CD3, CD4 and CD7 antigens immunogold method was used. We saw morphological differences between lymphocytes from MF and benign dermatoses. In MF, CD3 and CD4 were present rather in form of clusters placed on the surface of cell. On the contrary -CD3 to CD7 distribution analysis showed that these antigens were present rather individually, however there were seen clusters as well. In MF tumor stage labelling decreased in following order: CD7, CD3 and CD4. We also found...

FDA Approves Romidepsin for the Treatment of Cutaneous T-Cell Lymphoma

OncologySTAT Latest News — Tue, 10 Nov 2009 13:49:12 +0100

Romidepsin for injection has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least 1 prior systemic therapy. The US Food and Drug Administration granted... (Source: OncologySTAT Latest News)

FDA Approves Drug Treatment For Rare Cancer

Health News from Medical News Today — Tue, 10 Nov 2009 11:00:00 +0100

The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). Cutaneous T-cell lymphoma is a slow-growing cancer of infection-fighting white blood cells called T-lymphocytes. Most cases start with dry skin, red rash, and itching that can become severe. (Source: Health News from Medical News Today)

FDA Approves Drug Treatment For Rare Cancer

Cancer / Oncology News From Medical News Today — Tue, 10 Nov 2009 11:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Istodax Approved for Cutaneous T-Cell Lymphoma

Modern Medicine — Tue, 10 Nov 2009 00:00:00 +0100

(Source: Modern Medicine)

TCRgamma gene rearrangement in cutaneous T-cell lymphoma: comparative study of PCR with denaturing gradient gel electrophoresis and GeneScan analysis.

The British Journal of Dermatology — Tue, 10 Nov 2009 00:00:00 +0100

Conclusions BIOMED-2-GS analysis of the TCRgamma gene is as sensitive and specific as DGGE for CTCL diagnosis. In addition, BIOMED-2-GS is less time-consuming and gives more information concerning the size and nature of TCR-GR. PMID: 19906072 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

T-cell receptor γ gene rearrangement in cutaneous T-cell lymphoma: comparative study of polymerase chain reaction with denaturing gradient gel electrophoresis and GeneScan analysis

British Journal of Dermatology — Tue, 10 Nov 2009 00:00:00 +0100

Conclusions BIOMED-2-GS analysis of the TCR[gamma] gene is as sensitive and specific as DGGE for CTCL diagnosis. In addition, BIOMED-2-GS is less time-consuming and gives more information concerning the size and nature of TCR-GR. (Source: British Journal of Dermatology)

FDA Approves Drug Treatment for Rare Cancer

Food and Drug Administration — Mon, 09 Nov 2009 21:01:00 +0100

Cutaneous T-cell lymphoma affects about 1,500 Americans annually The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). (Source: Food and Drug Administration)

Istodax Approved for Cutaneous T-Cell Lymphoma

MedicineNet Cancer General — Mon, 09 Nov 2009 07:00:00 +0100

Title: Istodax Approved for Cutaneous T-Cell LymphomaCategory: Health NewsCreated: 11/6/2009 4:10:00 PMLast Editorial Review: 11/9/2009 (Source: MedicineNet Cancer General)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Extragenital lichen sclerosus et atrophicus mimicking cutaneous T-cell lymphoma: report of a case

Journal of Cutaneous Pathology — Mon, 09 Nov 2009 00:00:00 +0100

We report a case of extragenital LSA in which both histological patterns were present in the same clinically homogenous and stable lesion. A 27-year-old man presented with a history of white atrophic plaques on the trunk. A biopsy of an abdominal lesion revealed epidermal thinning, a superficial perivascular lymphoid cell infiltrate with focal epidermotropism, mild nuclear atypia and perinuclear halos. Immunophenotyping showed decreased CD5 and CD7, with a slight predominance of CD8-positive T-lymphocytes. All these changes were suggestive of MF. However, a repeat biopsy 3 months later from the same stable plaque revealed features diagnostic of LSA. LSA mimicking early MF histologically has been reported in genital skin. Conversely, MF may clinically and histopathologically resemble LSA. W...

FDA approves romidepsin (Istodax®) for treatment of cutaneous T-cell lymphoma

NeLM - Oncology — Mon, 09 Nov 2009 00:00:00 +0100

Source: BioSpace Area: News The FDA has approved romidepsin (Istodax®), a histone deacetylase (HDAC) inhibitor, for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. CTCL is a type of non-Hodgkin's lymphoma, but caused by a mutation of T cells, unlike most non-Hodgkin's lymphomas which are generally of B-cell origin. Approval was based upon two prospective multicentre, single-arm clinical studies in 167 patients, which reported overall objective disease response rates (primary efficacy endpoint) of 34% and 35%. The most common adverse reactions reported in the two studies were nausea, fatigue, infections, vomiting, anorexia, anaemia, thrombocytopenia, ECG T-wave changes, neutropenia and lymphopenia. (Source: NeLM - Oncolo...

Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant

British Journal of Dermatology — Mon, 09 Nov 2009 00:00:00 +0100

(Source: British Journal of Dermatology)

Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant.

The British Journal of Dermatology — Mon, 09 Nov 2009 00:00:00 +0100

Authors: Okada S, Nannya Y, Ota S, Takazawa Y, Yamamoto G, Kumano K, Izutsu K, Takahashi T, Chiba S, Kurokawa M PMID: 19903173 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma

Health News from Medical News Today — Sat, 07 Nov 2009 00:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma

Cancer / Oncology News From Medical News Today — Sat, 07 Nov 2009 00:00:00 +0100

Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response. (Source: Cancer / Oncology News From Medical News Today)

Histone Deacetylase Inhibitors in Cancer Therapy [REVIEW ARTICLE]

Journal of Clinical Oncology — Fri, 06 Nov 2009 23:02:20 +0100

Conclusion HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use. (Source: Journal of Clinical Oncology)

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma [Hematologic Malignancies]

Journal of Clinical Oncology — Fri, 06 Nov 2009 23:02:19 +0100

Conclusion The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL. (Source: Journal of Clinical Oncology)

FDA Approves Romidepsin for Refractory Cutaneous T-Cell Lymphoma

Medscape Today Headlines — Fri, 06 Nov 2009 21:58:08 +0100

The FDA has approved the HDAC inhibitor romidepsin for the treatment of cutaneous T-cell lymphoma in patients who have received at least 1 prior systemic therapy. Medscape Medical News (Source: Medscape Today Headlines)

Istodax Approved for Cutaneous T-Cell Lymphoma

Forbes.com Health News — Fri, 06 Nov 2009 20:32:00 +0100

It's a disfiguring cancer affecting the skin (Source: Forbes.com Health News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA Okays New Treatment for T-Cell Lymphoma

MedPage Today Product Alert — Fri, 06 Nov 2009 17:17:05 +0100

WASHINGTON (MedPage Today) -- The FDA has approved romidepsin (Istodax) for patients with cutaneous T-cell lymphoma who have received at least one prior systemic therapy. (Source: MedPage Today Product Alert)

FDA Approves Gloucester Pharmaceuticals' Istodax for Patients with Cutaneous T-cell Lymphoma

Drugs.com - New Drug Approvals — Fri, 06 Nov 2009 15:46:08 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 5, 2009 - Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved Istodax (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have... (Source: Drugs.com - New Drug Approvals)

FDA approves romidepsin for cutaneous T-cell lymphoma

HemOncToday.com — Fri, 06 Nov 2009 10:56:00 +0100

(Source: HemOncToday.com)

In Mycosis Fungoides, Immunophenotypes May Vary Between Skin and Blood

Medscape Internal Medicine Headlines — Wed, 04 Nov 2009 13:35:05 +0100

T-cell immunophenotype of mycosis fungoides involving the skin varies from that involving the blood in more than half the cases of this cutaneous T-cell lymphoma. Medscape Medical News (Source: Medscape Internal Medicine Headlines)

Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome

Journal of Cutaneous Pathology — Wed, 04 Nov 2009 00:00:00 +0100

Immunodeficiency-related lymphoproliferative disorders (IR-LPD) may occur in the setting of immunosuppressive therapy with methotrexate and TNF-[alpha] antagonists. As far as we are aware, this is the first report of an Epstein-Barr virus-associated B-cell lymphoproliferative disorder, secondary to methotrexate therapy in a patient with mycosis fungoides/Sézary syndrome. Curry JL, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome. (Source: Journal of Cutaneous Pathology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

[Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides.]

Annales de Dermatologie et de Cenereologie — Sun, 01 Nov 2009 00:00:00 +0100

We report the case of a young man still in complete remission for transformed mycosis fungoides 14 years after autologous stem cell transplantation. CASE REPORT: A 25-year-old man presenting eczema-like patches since childhood was treated by chemotherapy for multiple lymphadenopathies considered as Hodgkin's lymphoma. He was referred with diffuse skin tumours and infiltrated patches. Histology of tumour samples revealed atypical T-cell infiltrate with epidermotropism and presence of more than 25% of large CD30-positive cells. Non-infiltrated patches showed small T-cell lymphoma with epidermotropism. Histological verification of a previous lymphadenopathy confirmed the diagnosis of transformed mycosis fungoides. Despite multiple courses of chemotherapy, the disease progressed, with neurolog...

Identification of Key Regions and Genes Important in the Pathogenesis of Sezary Syndrome by Combining Genomic and Expression Microarrays

Cancer Research — Thu, 29 Oct 2009 04:08:15 +0100

In this study, we used single nucleotide polymorphism and comparative genomic hybridization array to study DNA copy number changes and loss of heterozygosity for 28 patients affected by Sézary syndrome (SS), a rare form of cutaneous T-cell lymphoma (CTCL). Our data identified, further confirming previous studies, recurrent losses of 17p13.2-p11.2 and 10p12.1-q26.3 occurring in 71% and 68% of cases, respectively; common gains were detected for 17p11.2-q25.3 (64%) and chromosome 8/8q (50%). Moreover, we identified novel genomic lesions recurring in >30% of tumors: loss of 9q13-q21.33 and gain of 10p15.3-10p12.2. Individual chromosomal aberrations did not show a significant correlation with prognosis; however, when more than three recurrent chromosomal alterations (gain or loss) wer...

A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis Vulgaris

Karger Publishers — Mon, 26 Oct 2009 23:00:00 +0100

Case Rep Dermatol 2009;1:60-65 (DOI:10.1159/000249148) (Source: Karger Publishers)

Serum interleukin-27 levels in patients with cutaneous T-cell lymphoma

Clinical And Experimental Dermatology — Thu, 22 Oct 2009 23:00:00 +0100

(Source: Clinical And Experimental Dermatology)

Current and Emerging Treatment Options in Cutaneous T-cell lymphoma

Clinical Care Options Oncology - Lung Cancer — Wed, 21 Oct 2009 12:00:00 +0100

CCO Expert Recap - John A. Zic, MD, discusses the pathogenesis, staging, and treatment options for patients with cutaneous T-cell lymphoma. (Source: Clinical Care Options Oncology - Lung Cancer)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Current and Emerging Treatment Options in Cutaneous T-cell lymphoma

Clinical Care Options Oncology - Lung Cancer — Wed, 21 Oct 2009 12:00:00 +0100

CCO Expert Recap - John A. Zic, MD, discusses the pathogenesis, staging, and treatment options for patients with cutaneous T-cell lymphoma. (Source: Clinical Care Options Oncology - Lung Cancer)

Current and Emerging Treatment Options in Cutaneous T-Cell Lymphoma

Clinical Care Options Oncology - Lymphoma — Wed, 21 Oct 2009 00:00:00 +0100

CCO Slideset - Downloadable slideset on the standards of care and emerging novel therapies for the treatment of cutaneous T-cell lymphoma. (Source: Clinical Care Options Oncology - Lymphoma)

Current and Emerging Treatment Options in Cutaneous T-Cell Lymphoma

Clinical Care Options Oncology - Lymphoma — Wed, 21 Oct 2009 00:00:00 +0100

CCO Slideset - Downloadable slideset on the standards of care and emerging novel therapies for the treatment of cutaneous T-cell lymphoma. (Source: Clinical Care Options Oncology - Lymphoma)

Slideset: Current and Emerging Treatment Options in Cutaneous T-Cell Lymphoma

Clinical Care Options Oncology - Lymphoma — Wed, 21 Oct 2009 00:00:00 +0100

CCO Slideset - Downloadable slideset on the standards of care and emerging novel therapies for the treatment of cutaneous T-cell lymphoma. (Source: Clinical Care Options Oncology - Lymphoma)

About the cutaneous targets of bexarotene in CTCL patients

Experimental Dermatology — Tue, 20 Oct 2009 23:00:00 +0100

Please cite this paper as: About the cutaneous targets of bexarotene in CTCL patients. Experimental Dermatology 2009.Abstract: There are several approved therapies for cutaneous T-cell lymphoma (CTCL). The retinoids are one of the major biologic response modifiers used in CTCL, producing good response rates but few complete responses. Bexarotene has been demonstrated to act on malignant T-cells by inducing their apoptosis, but nothing is known about its role on keratinocytes and Langerhans cells. Immunohistochemical analysis using CD1a, HLA-DR, ICAM-1 (activation markers), CD95 and CD40 (apoptosis markers) was conducted on frozen sections of bexarotene-exposed cutaneous explants and skin biopsy specimens from patients treated with bexarotene. None of the studied markers was significantly m...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Absence of modulation of CD4+CD25high regulatory T cells in CTCL patients treated with bexarotene

Experimental Dermatology — Tue, 20 Oct 2009 23:00:00 +0100

Please cite this paper as: Absence of modulation of CD4+CD25high regulatory T cells in CTCL patients treated with bexarotene. Experimental Dermatology 2009.Abstract: Cutaneous T-cell lymphoma (CTCL) are a heterogeneous group of lymphoproliferative disorders, characterized by the infiltration of the epidermis by mature and activated malignant CD4+ T-lymphocytes. Retinoids such as retinoic acid and synthetic analogues have long been used alone or in combination with other therapies for CTCL. Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refractory to at least one systemic therapy. Recently, six cases in which the initiation of bexarotene therapy for CTCL was associated with the progression of internal disease d...

Mycosis fungoides presenting as a pustular eruption

Journal of the American Academy of Dermatology — Sat, 17 Oct 2009 12:58:00 +0100

A 78-year-old woman presented with a generalized and figurate erythema with marginal lamellar scaling and pustulation. In addition, scaly, erythematous, and atrophic plaques with occasional pustules were found on the trunk, arms and legs (). Several skin biopsy specimens showed two distinct phenomena: a) a sub- and intracorneal pustule and b) a bandlike lymphocytic infiltrate of atypical lymphocytes with cerebriform nuclei. The atypical lymphocytes showed extensive epidermotropism and intraepidermal abscess formation (). Immunohistochemically the atypical lymphocytes were CD45-R0+, CD3+, CD4+ and CD8+ cells. Molecular biological analysis by polymerase chain reaction showed initially no T-cell-receptor rearrangements. At follow-up, the patient was noted to have developed clinically typical ...

Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation

Clinical And Experimental Dermatology — Fri, 09 Oct 2009 23:00:00 +0100

A 56-year-old male patient had a history of mantle-cell lymphoma, which was treated with polychemotherapy and reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation (ASCT) from his healthy sister with an identical human leucocyte antigen profile. Six years after transplantation, the patient developed asymptomatic eczema-like cutaneous lesions. Histologically the lesions contained a dense superficial lichenoid infiltrate, mainly consisting of CD4+ atypical medium to large lymphocytes showing indented hyperchromatic nuclei. In situ hybridization for Epstein[ndash]Barr virus was negative. PCR amplification of the T-cell receptor-[gamma] chain gene from several lesions revealed a monoclonal rearrangement without clonal variation. Two-colour fluorescence in situ hybr...

Cutaneous B-cell lymphoma with histologic features of mycosis fungoides

Journal of the American Academy of Dermatology — Thu, 08 Oct 2009 00:00:00 +0100

Histologic examination of skin biopsy specimens from a 57-year-old man with a pruritic rash on his chest, abdomen, and thighs revealed a dense atypical dermal lymphoid infiltrate bordering the dermoepidermal junction and scattered intraepithelial lymphocytes. Histopathologic and clinical features were suggestive of mycosis fungoides. Immunophenotyping studies, however, identified CD20+ B lymphocytes with aberrant expression of CD43. Clonal immunoglobulin gene rearrangement was demonstrated, and no clonal T-cell gene rearrangement was identified. Morphologic and immunophenotypic features were most consistent with extranodal marginal zone B-cell lymphoma. Systemic evaluation identified involvement of the bone marrow and possibly the peripheral blood, spleen, and splenic lymph nodes. Cutaneou...

Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides.

Clinical Lymphoma and Myeloma — Thu, 01 Oct 2009 00:00:00 +0100

We report 3 patients whose tumor-stage mycosis fungoides was not sufficiently controlled by several preceding systemic therapies, including liposome-encapsulated doxorubicin. All patients experienced excellent improvement with 250 mg/m2 gemcitabine weekly, a low-dose regimen that is predicted to be less toxic compared with standard-dose gemcitabine. PMID: 19858049 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Panel Backs Romidepsin as Second-Line CTCL Therapy

Skin and Allergy News — Wed, 30 Sep 2009 23:00:00 +0100

SILVER SPRING, MD. — The Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10-0, with 1 abstention, that two single-arm trials of romidepsin show that the drug has a favorable risk-benefit profile as a second-line treatment for patients with cutaneous T-cell lymphoma. (Source: Skin and Allergy News)

Antibody-based therapy of leukaemia

Expert Reviews in Molecular Medicine — Wed, 30 Sep 2009 18:21:02 +0100

Review ArticlesJohn C. Morris, Thomas A. Waldmann, Expert Reviews in Molecular Medicine, Volume 11 , pp e29AbstractOver the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and S zary syndrome, and adult T cell leukaemia and lymphoma. In addition, rituximab has demonstrated...

Etanercept/infliximab: Cutaneous T cell lymphoma: 2 case reports

Reactions — Wed, 30 Sep 2009 16:32:33 +0100

(Source: Reactions)

An outbreak of furniture related dermatitis ('sofa dermatitis') in Finland and the UK: history and clinical cases

Journal of the European Academy of Dermatology and Venereology — Tue, 29 Sep 2009 23:00:00 +0100

In February 2007, an epidemic of severe dermatitis from Chinese recliner chairs and sofas started to unfold first in Finland and a few months later in the UK. Some patients reacted in patch tests (PTs) strongly to the material of their furniture, either leather or fabric. There have been hundreds of reports of chair or sofa dermatitis from Finland and the UK, with all cases linked to the same furniture factory in China. Clinical findings in both countries were very similar and unlike any known dermatosis. Many cases have been quite severe, resembling mycosis fungoides or septic infections, requiring hospitalization. Commercial PTs did not reveal the cause but a fungicide was strongly suspected, although such use was denied by the factory. The laboratory of Malmö University Dermatology Cli...

Drug That Crosses Blood-Brain Barrier Reduces Formation of Brain Metastases in Mice

National Institutes of Health (NIH) News Releases — Tue, 29 Sep 2009 17:05:00 +0100

The drug vorinostat is able to cross the blood-brain barrier and reduce the development of large metastatic tumors in mice brains by 62 percent when compared to mice that did not receive the drug, according to a new study. In humans, the drug has been approved by the U.S. Food and Drug Administration for the treatment of a cancer called cutaneous T-cell lymphoma but can be used experimentally to study its effectiveness against other cancers. This research, by investigators at the National Cancer Institute (NCI), part of the National Institutes of Health, and their collaborators, appears online Sept. 29, 2009, in Clinical Cancer Research. (Source: National Institutes of Health (NIH) News Releases)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sézary syndrome

British Journal of Dermatology — Mon, 28 Sep 2009 23:00:00 +0100

(Source: British Journal of Dermatology)

A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders.

Clinical Cancer Research — Mon, 28 Sep 2009 23:00:00 +0100

CONCLUSIONS: SGN-30 was clinically active in 16 of 23 patients with heavily pretreated pc-ALCL, LyP, and T-MF and was well tolerated in this study. (Clin Cancer Res 2009;15(19):6217-24). PMID: 19789316 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Increase in gamma-globin mRNA content in human erythroid cells treated with angelicin analogs.

International Journal of Hematology — Thu, 24 Sep 2009 23:00:00 +0100

Authors: Lampronti I, Bianchi N, Zuccato C, Dall'acqua F, Vedaldi D, Viola G, Potenza R, Chiavilli F, Breveglieri G, Borgatti M, Finotti A, Feriotto G, Salvatori F, Gambari R The aim of the present study was to identify molecular analogs of angelicin (ANG) able to increase erythroid differentiation of K562 cells and expression of gamma-globin genes in human erythroid precursor cells, with low effects on apoptosis. ANG-like molecules are well-known photosensitizers largely used for their antiproliferative activity in the treatment of different skin diseases (i.e., psoriasis, vitiligo, eczema, and mycosis fungoides). To verify the activity of these derivatives, we employed three experimental cell systems: (1) the human leukemic K562 cell line, (2) K562 cell clones stably transfected with...

THE CUTTING EDGE: Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma

Archives of Dermatology — Sun, 20 Sep 2009 23:00:00 +0100

(Source: Archives of Dermatology)

Cutaneous T cell lymphoma and graft-versus-host disease: A comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells.

Clinical Immunology — Fri, 18 Sep 2009 23:00:00 +0100

Authors: Rao V, Saunes M, Jørstad S, Moen T Extracorporeal photochemotherapy (ECP) is a well established treatment for both cutaneous T cell lymphoma (CTCL) and graft-versus-host disease (GVHD). However, the general effector mechanism is not fully settled. Twenty-four patients with CTCL and 14 patients with GVHD were included to assess the relative numbers of regulatory T cells (Treg) and any change in the serum cytokine profile during 6 months of ECP therapy. The relative amount of Treg cells was twice as high in CTCL compared to GVHD and healthy controls. TGF-beta was on average three times higher in GVHD than in CTCL. Both patient groups had a small but significant increase in TGF-beta after treatment. Our results indicate a strengthened Treg function as a result of ECP. Elevat...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Lentigines following narrow-band ultraviolet B phototherapy for mycosis fungoides

Clinical And Experimental Dermatology — Mon, 14 Sep 2009 23:00:00 +0100

(Source: Clinical And Experimental Dermatology)

Betesil (betamethasone) 2.250mg Medicated Plaster - New Product

NeLM - Dermatology — Sat, 12 Sep 2009 23:00:00 +0100

Source: No information given Area: Other Library Updates > SPC Changes Betesil is a new product indicated for the treatment of inflammatory skin disorders which do not respond to treatment with less potent corticosteroids, such as eczema, lichenification, lichen planus, granuloma annulare, palmoplantar pustulosis and mycosis fungoides. Due to its particular pharmaceutical form, BETESIL is suitable for chronic plaque psoriasis localized in difficult to treat areas (e.g. knees, elbows and anterior face of the tibia on an area not greater than 5% of the body surface). (Source: NeLM - Dermatology)

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

Cancer Science — Wed, 09 Sep 2009 23:00:00 +0100

Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL). A phase I trial of oral vorinostat was conducted in Japanese patients with malignant lymphoma. Vorinostat 100 or 200 mg was administered twice daily for 14 consecutive days followed by a 1-week rest interval. Of 10 patients enrolled, four had follicular lymphoma (FL), two mantle cell lymphoma (MCL), two diffuse large B-cell lymphoma, and two CTCL (median age, 60 years; median number of prior regimens, 3). Vorinostat was well tolerated up to 200 mg with only one of six patients developing a dose-limiting toxicity (DLT; Grade 3 anorexia/hypokalemia). Common Grade 3 events were reversible neutropenia (30%), thrombocytopenia, and hypermagnes...

Papular mycosis fungoides: two new cases of a recently described clinicopathological variant of early mycosis fungoides

Journal of Cutaneous Pathology — Mon, 07 Sep 2009 23:00:00 +0100

Conclusion: Papular MF is a new variant of early MF characterized by a good prognosis in the long term follow- up. Thus, it should be added to the long list of clinicopathologic subtypes of MF. Martorell-Calatayud A, Botella-Estrada R, Sanmartín-Jimenez O, Requena C, Guillén-Barona C, Sangueza OP. Papular mycosis fungoides: two new cases of a recently described clinicopathological variant of early mycosis fungoides. (Source: Journal of Cutaneous Pathology)

FDA Panel Backs Romidepsin, 10-0-1, for CTCL

OncologySTAT Latest News — Thu, 03 Sep 2009 16:13:00 +0100

SILVER SPRING, Md. (EGMN) - The Food and Drug Administration's Oncologic Drugs Advisory Committee voted 10-0, with one abstention, at a meeting on Sept. 2, that two single-arm trials of romidepsin show... (Source: OncologySTAT Latest News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin For Approval For Cutaneous T-cell Lymphoma

Cancer / Oncology News From Medical News Today — Thu, 03 Sep 2009 13:00:00 +0100

Gloucester Pharmaceuticals announced that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system. (Source: Cancer / Oncology News From Medical News Today)

FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma

HSMN NewsFeed — Thu, 03 Sep 2009 03:25:10 +0100

CAMBRIDGE, Mass.--(HSMN NewsFeed)--Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romideps... Biopharmaceuticals, Oncology, FDAGloucester Pharmaceuticals, romidepsin, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)

FDA panel supports approval of romidepsin for cutaneous T-cell lymphoma

NeLM - Oncology — Wed, 02 Sep 2009 23:00:00 +0100

Source: BioSpace Area: News The FDA's Oncologic Drug Advisory Committee has voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). A New Drug Application is currently under review with the FDA. CTCL is caused by a mutation of T cells, unlike most non-Hodgkin's lymphomas which are generally of B-cell origin, and affects the skin, causing plaques, patches, erythroderma and/or tumours and can involve other organs, including the lymph nodes and viscera. Romidepsin belongs to a new class of cancer drugs known as histone deacetylase inhibitors. (Source: NeLM - Oncology)

FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma

Drugs.com - New Drug Applications — Wed, 02 Sep 2009 21:00:33 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 2, 2009 - Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to... (Source: Drugs.com - New Drug Applications)

Controversies in the management of the cutaneous T cell lymphomas

Dermatologic Therapy — Mon, 31 Aug 2009 23:00:00 +0100

The primary cutaneous T cell lymphomas (CTCL) encompass all malignancies of the T cell where the skin is the primary organ of involvement. The diagnosis of a CTCL variant can be detoured by a number of obstacles including the slow evolution of the disease into a classic clinical and pathologic pattern. A realistic goal of early stage treatment is to reduce the likelihood of progression to a more advanced stage, not to achieve a cure. No studies have adequately compared the different systemic agents in patients with advanced CTCL so the clinician is left to act in the best interest of the patient with what evidence is available. When using the systemic agents, a "start low and go slow" strategy may offer patients several advantages. Dermatologists are uniquely trained to diagnose and to man...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Original paper Angiogenesis assessment in patients with mycosis fungoides

Articles of Advances in Dermatology and Allergology - TERMEDIA publishing house — Sun, 30 Aug 2009 09:03:40 +0100

Conclusions: The studied factor does not fulfil the criteria for a biomarker distinguishing mycosis fungoides and parapsoriasis en grandes plaques, despite being a characteristic feature of advanced mycosis fungoides, and increased angiogenesis measured by CD34 expression is a poor prognostic marker of the disease. (Source: Articles of Advances in Dermatology and Allergology - TERMEDIA publishing house)

Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinaemia

Internal Medicine Journal — Thu, 27 Aug 2009 23:00:00 +0100

We present the case of a patient who suffered chronic active hepatitis C, cryoglobulinaemia and B-cell lymphoma and was later complicated by cutaneous T-cell lymphoma (CTCL). (Source: Internal Medicine Journal)

Frequencies of non-Hodgkin’s lymphoma subtypes in Kuwait: comparisons between different ethnic groups

Annals of Hematology — Thu, 27 Aug 2009 16:33:11 +0100

Abstract There is a wide variation in the prevalence of various subtypes of non-Hodgkin’s lymphoma worldwide. The aim of this study was to determine the relative frequency of different subtypes of non-Hodgkin’s lymphoma in Kuwait based on the Revised European–American Lymphoma (REAL) classification. From 1998 to 2006, 738 subjects were included that were registered with non-Hodgkin’s lymphoma in the population-based cancer registry at the Kuwait Cancer Control Center. Expert pathologists reviewed histological slides from all subjects. We performed detailed immunohistochemical studies and classified subjects based on the REAL classification. The prevalence of different types of non-Hodgkin's lymphoma was determined based on age, sex, site of disease, and ethnicity. ...

Yaupon locks up phase II Clearazide trial

Cancer Network — Mon, 24 Aug 2009 12:00:00 +0100

Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma. (Source: Cancer Network)

Folliculotropic Mycosis Fungoides with Severe Hepatic Failure due to Hepatic Involvement.

Acta Derm Venereol A... — Thu, 20 Aug 2009 13:32:03 +0100

Authors: Shibata S, Sugaya M, Minatani Y, Fujita H, Tsunemi Y, Miyagaki T, Saeki H, Kikuchi K, Asai T, Kurokawa M, Tamaki K PMID: 19688164 [PubMed - in process] (Source: Acta Derm Venereol A...)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Mycosis fungoides with recurrent Hodgkin's lymphoma and diffuse large B-cell lymphoma.

Acta Derm Venereol A... — Thu, 20 Aug 2009 13:32:03 +0100

Authors: Miyagaki T, Sugaya M, Minatani Y, Fujita H, Hangaishi A, Kurokawa M, Takazawa Y, Tamaki K PMID: 19688163 [PubMed - in process] (Source: Acta Derm Venereol A...)

Gloucester Pharmaceuticals Announces FDA Advisory Committee Meeting To Discuss Romidepsin New Drug Application

Health News from Medical News Today — Wed, 19 Aug 2009 04:00:00 +0100

Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009. CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system. (Source: Health News from Medical News Today)

Short Communication: Activation of Latent HIV Type 1 Gene Expression by Suberoylanilide Hydroxamic Acid (SAHA), an HDAC Inhibitor Approved for Use to Treat Cutaneous T Cell Lymphoma

AIDS Research and Human Retroviruses — Tue, 18 Aug 2009 15:54:09 +0100

AIDS Research and Human Retroviruses , Vol. 0, No. 0. (Source: AIDS Research and Human Retroviruses)

Gloucester Pharmaceuticals Announces FDA Advisory Committee Meeting to Discuss Romidepsin New Drug Application

Drugs.com - New Drug Applications — Tue, 18 Aug 2009 14:15:04 +0100

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 17, 2009 - Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting... (Source: Drugs.com - New Drug Applications)

Differentiation and Apoptosis in UVA-Irradiated Cells Treated with Furocoumarin Derivatives

Annals of the New York Academy of Sciences — Fri, 14 Aug 2009 23:00:00 +0100

In this review we summarize the structure and biological effects of linear and angular psoralens. These compounds exhibit interesting biological effects on the cell cycle, apoptosis and differentiation. These molecules should be considered promising drugs in the therapy of several diseases, including psoriasis, mycosis fungoides and cancer. Also, preclinical data demonstrate a possible use of these molecules for the treatment of [beta]-thalassemia and other hematological disorders. (Source: Annals of the New York Academy of Sciences)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Extracorporeal photopheresis: Past, present, and future

Journal of the American Academy of Dermatology — Sun, 09 Aug 2009 23:00:00 +0100

Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological agents, ECP is an established and effective therapy for advanced cutaneous T-cell lymphoma. ECP has also shown promising efficacy in a number of other severe and difficult-to-treat conditions, including systemic sclerosis, graft-versus-host disease, prevention and treatment of rejection in solid organ transplantation, and Crohn disease. Furthermore, the use of ECP in some of these conditions may allow a significant reduction in the use of systemic steroids and other immunosuppressants, reducing long-term morbidity and mortality. The accumulated experience shows ECP to be well tolerated, with no clinically significant sid...

Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis

Journal of Cutaneous Pathology — Thu, 06 Aug 2009 23:00:00 +0100

Conclusion: FoxP3-positive T cells are less frequently encountered in MF than in inflammatory dermatoses. FoxP3-positive T cells occur in higher proportions in the dermis than in the epidermis and probably correlate with coexisting inflammatory components. CTCL neoplastic cells do not typically express a Treg phenotype and are associated with low numbers of FoxP3-positive Tregs in the infiltrate. FoxP3 expression by immunohistochemistry may aid histologic evaluation of these conditions. Wada DA, Wilcox RA, Weenig RH, Gibson LE. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis. (Source: Journal of Cutaneous Pathology)

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

British Journal of Haematology — Tue, 04 Aug 2009 23:00:00 +0100

This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual. (Source: British Journal of Haematology)

HDAC inhibitor-based therapies and haematological malignancy

Annals of Oncology — Mon, 03 Aug 2009 23:00:00 +0100

Reversible acetylation mediated by histone deacetylase (HDAC) influences a broad repertoire of physiological processes, many of which are aberrantly controlled in tumour cells. Since HDAC inhibition prompts tumour cells to enter apoptosis, small-molecule HDAC inhibitors have been developed as a new class of mechanism-based anticancer agent, many of which have entered clinical trials. While the clinical picture is evolving and the precise utility of HDAC inhibitors remains to be determined, it is noteworthy that certain tumour types undergo a favourable response, in particular haematological malignancies. Vorinostat (suberoylanilide hydroxamic acid) has been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease. Here, we discuss develo...

Folliculotropic mycosis fungoides in a psoriatic patient under methotrexate treatment

JDDG — Sun, 02 Aug 2009 23:00:00 +0100

We report a case of folliculotropic mycosis fungoides developing in the months following methotrexate therapy in a psoriatic patient. This lymphoma did not regress after stopping the antipsoriatic treatment. There is a known relationship between the use of immunosuppressive therapies and the development of lymphoproliferative malignancies. However these lymphomas are mainly B-cell non-Hodgkin lymphomas associated with Epstein-Barr virus. In our patient the short period of time from the beginning of the immunosuppressive treatment to the occurrence of the T-cell lymphoma does not support a strong causal relationship between the drug intake and the development of mycosis fungoides. To the best of our knowledge, this is the first case of folliculotropic mycosis fungoides in a patient treated ...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Canine cutaneous epitheliotropic T-cell lymphoma with vesiculobullous lesions resembling human bullous mycosis fungoides.

Veterinary Dermatology — Fri, 31 Jul 2009 23:00:00 +0100

Authors: Bizikova P, Linder KE, Suter SE, Van Wettere AJ, Olivry T The broad spectrum of clinical signs in canine cutaneous epitheliotropic T-cell lymphoma mimics many inflammatory skin diseases and is a diagnostic challenge. A 13-year-old-male castrated golden retriever crossbred dog presented with multifocal flaccid bullae evolving into deep erosions. A shearing force applied to the skin at the periphery of the erosions caused the epidermis to further slide off the dermis suggesting intraepidermal or subepidermal separation. Systemic signs consisted of profound weight loss and marked respiratory distress. Histologically, the superficial and deep dermis were infiltrated by large, CD3-positive neoplastic lymphocytes and mild epitheliotropism involved the deep epidermis, hair follicle w...

Comparison of seropositivity of human T lymphotropic virus type 1 in mycosis fungoides patients and normal volunteers: A case-control study and review of literature

Indian Journal of Dermatology, Venereology and Leprology — Thu, 30 Jul 2009 10:54:32 +0100

Conclusion:</b> This study showed that MF does not correlate with HTLV-1 infection in Iran. (Source: Indian Journal of Dermatology, Venereology and Leprology)

Extracorporeal photopheresis: what is it and when should it be used?

Clinical And Experimental Dermatology — Tue, 28 Jul 2009 23:00:00 +0100

Extracorporeal photopheresis (ECP) is a technique that was developed > 20 years ago to treat erythrodermic cutaneous T-cell lymphoma (CTCL). The technique involves removal of peripheral blood, separation of the buffy coat, and photoactivation with a photosensitizer and ultraviolet A irradiation before re-infusion of cells. More than 1000 patients with CTCL have been treated with ECP, with response rates of 31[ndash]100%. ECP has been used in a number of other conditions, most widely in the treatment of chronic graft-versus-host disease (cGvHD) with response rates of 29[ndash]100%. ECP has also been used in several other autoimmune diseases including acute GVHD, solid organ transplant rejection and Crohn's disease, with some success. ECP is a relatively safe procedure, and side-effects are ...

Photopheresis with UV-A light and 8-methoxypsoralen leads to cell death and to release of blebs with anti-inflammatory phenotype in activated and non-activated lymphocytes.

Biochemical and Biophysical Research communications — Tue, 28 Jul 2009 16:26:43 +0100

Conclusion: PUVA treatment exerts anti-inflammatory effects by inducing apoptosis and apoptotic cell-derived blebs with immune suppressive surface composition. PMID: 19501044 [PubMed - indexed for MEDLINE] (Source: Biochemical and Biophysical Research communications)